Thrombocytopenia and neutropenia limited repeat dosing. Although limited clinical activity was detected, the dose-escalation phase was stopped early without establishing an MTD. The study was registered with ClinicalTrials.gov (NCT03106428).

MEDI7247 (human anti-ASCT2 antibody conjugated with pyrrolobenzodiazepine (PBD)) and MEDI7519 (MEDI7247 without PBD drug conjugate) and an isotype control antibody drug conjugate construct were conjugated with p-isothiocyanatobenzyl-deferoxamine (Df) and radiolabeled with zirconium-89. Preclinical biodistribution analyses of [Zr]Zr-Df-MEDI7247 and [Zr]Zr-Df-MEDI7519 showed the biodistribution pattern of anti-ASCT2 ADC MEDI7247 was similar to parental MEDI7519, and both antibodies showed specific tumor uptake compared to an isotype control ADC. This study highlights an important role nuclear medicine imaging techniques can play in early preclinical assessment of drug specificity as part of the drug development pipeline.

Three novel agents effective in R/R cHL were introduced; brentuximab-vedotin (BV), anti-CD30 antibody-drug conjugate3 and the programmeddeath-1 (PD-1) blocking antibodies, nivolumab and pembrolizumab4, 5 has been approved. Giving decision about novel therapies, major adverse events, such as neuropathy for BV and immune related events for PD1-blockers. Optimal timing of BV and PD1-blockers and treatment strategies in case of resistance to novel agents are critical questions for the future of cHL management, which hopefully will be answered by the results of clinical trials and real-world data.